Highlights in Leukemia and Lymphoma

Nivolumab Outperforms Brentuximab Vedotin in Newly Diagnosed Advanced Hodgkin Lymphoma Nivolumab (Opdivo, Bristol Myers Squibb) plus doxorubicin, vinblastine, and dacarbazine (AVD) significantly improved progression-free survival (PFS) […]